FDA Approval

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

Memo Therapeutics' Potravitug shows promise in a Phase II trial, offering the first real weapon against a common virus that threatens kidney transplants.

Merck secures a pivotal FDA approval for its CAPVAXIVE vaccine, offering new hope for at-risk youth and challenging rivals in the high-stakes pneumococcal market.

Early trial data for a novel antibody-drug conjugate shows a 32% response rate in a hard-to-treat patient group, signaling a potential new front in precision oncology.

After a 20-year drought, positive Phase 3 data for oral olorofim signals a safer, potent new option against a deadly fungus, promising a major market shake-up.

AB Science has secured a US patent until 2042 for masitinib, a targeted therapy for advanced prostate cancer, offering new hope where few options exist.

Gene therapy firm uniQure plans a 2026 FDA submission for AMT-130, a potential first disease-modifying treatment for Huntington's, on an accelerated track.

Researchers at Children's Hospital of Philadelphia have pioneered a personalized cartilage graft that could revolutionize surgery for a life-threatening infant airway condition.

Opus Genetics unveils a multi-program gene therapy pipeline, backed by a robust financial runway, aiming to systematically dismantle inherited retinal diseases.

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

With a landmark therapy for Sanfilippo Syndrome nearing the FDA, Spruce adds veteran marketing and finance chiefs. A look at the talent behind the transition.

Novartis unveils groundbreaking Phase III data for Rhapsido, offering hope as the first potential targeted therapy for 29 million chronic hive sufferers.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.

Interim Phase 3 data shows Otsuka's VOYXACT not only meets surrogate endpoints but preserves kidney function, a strategic masterstroke in the competitive nephrology market.

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

With an FDA decision just weeks away, Ionis's olezarsen could redefine care for a debilitating condition, marking a pivotal moment for RNA-targeted medicine.

ADC Therapeutics' lymphoma drug ZYNLONTA shows promise in a Phase 3 trial, but a concerning safety signal in older patients complicates its path to market.